Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Molecular and Cellular Biology

Abstract 604: Styrene compounds induce apoptosis in triple negative breast cancer cell lines.

Checo J. Rorie, Shaina L. Richardson, Agape C. Lucas, Phillip A. Thomas, Kashenya M. Gurley and Marion A. Franks
Checo J. Rorie
North Carolina A&T State Univ., Greensboro, NC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaina L. Richardson
North Carolina A&T State Univ., Greensboro, NC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Agape C. Lucas
North Carolina A&T State Univ., Greensboro, NC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Phillip A. Thomas
North Carolina A&T State Univ., Greensboro, NC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kashenya M. Gurley
North Carolina A&T State Univ., Greensboro, NC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marion A. Franks
North Carolina A&T State Univ., Greensboro, NC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2013-604 Published April 2013
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC

Abstract

Triple negative breast cancer (TNBC) is a rare basal-like subtype of breast cancer that is highly aggressive due to its invasiveness and metastatic properties. TNBC is characterized by the loss or low expression of estrogen receptor, progesterone receptor, and HER2 proteins which have been targeted and established as somewhat effective therapy regiments in other breast cancer subtypes including luminal breast cancer. Since triple negative tumors are missing these established drug targets, there has been little advancement in the establishment of drug therapies to specifically target this breast cancer subtype and therefore the need for novel therapeutics in treating TNBC still remains. Previous reports have suggested that PARP inhibitors show promise in potentiating the effectiveness of other known chemotherapeutics. Styrene compounds are volatile organic compounds that have a similar structural composition to some known PARP inhibitors. Our group has developed styrene compounds composed of a 3-nitro group on the A ring and varying aryl groups in the B ring of the styrene, and then tested their biological effects on luminal and TNBC cell lines. In this study, four different styrene compounds were used to treat the luminal breast cancer cell line HCC70 and the triple negative breast cancer cell line HCC1806. The breast cancer cells were exposed to a 10, 100, and 1000 μM titration over a 24hr time period. The apoptotic effect on these cell lines were analyzed and measured via qualitative and quantitative methods. We show here that light microscopy revealed a classic apoptotic dose-response to all of the styrene compounds in the cell lines. We also used the cell viability and MTT assays to reveal a dose-response decrease in cell viability and increase in cell death to the titration of the styrene compounds. This preliminary data show that these compounds have the ability to induce apoptosis in luminal and triple negative breast cancer cell lines. Our preliminary results lead us to believe that these styrenes could represent a new chemotherapeutic treatment for Triple Negative Breast Cancer and potentially other breast cancer subtypes.

Citation Format: Checo J. Rorie, Shaina L. Richardson, Agape C. Lucas, Phillip A. Thomas, Kashenya M. Gurley, Marion A. Franks. Styrene compounds induce apoptosis in triple negative breast cancer cell lines. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 604. doi:10.1158/1538-7445.AM2013-604

  • ©2013 American Association for Cancer Research
Back to top
Cancer Research: 73 (8 Supplement)
April 2013
Volume 73, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 604: Styrene compounds induce apoptosis in triple negative breast cancer cell lines.
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 604: Styrene compounds induce apoptosis in triple negative breast cancer cell lines.
Checo J. Rorie, Shaina L. Richardson, Agape C. Lucas, Phillip A. Thomas, Kashenya M. Gurley and Marion A. Franks
Cancer Res April 15 2013 (73) (8 Supplement) 604; DOI: 10.1158/1538-7445.AM2013-604

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 604: Styrene compounds induce apoptosis in triple negative breast cancer cell lines.
Checo J. Rorie, Shaina L. Richardson, Agape C. Lucas, Phillip A. Thomas, Kashenya M. Gurley and Marion A. Franks
Cancer Res April 15 2013 (73) (8 Supplement) 604; DOI: 10.1158/1538-7445.AM2013-604
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Molecular and Cellular Biology

  • Abstract DDT02-01: Inhibition of the AAA-ATPase p97 with the first in class inhibitor CB-5083 as a novel approach to treat cancer
  • Abstract RAOS15-03: Pancreatic tumor stroma as a therapeutic target
  • Abstract LB-289: Interaction between miR-155 and Quaking in the innate immune response and leukemia
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013
  • Abstract LB-001: Impact of direct physician engagement with racial/ethnic minorities for oncology clinical trial access and accrual model
  • Abstract LB-107: EV-TRACK: transparent reporting and centralizing knowledge of extracellular vesicles to support the validation of extracellular vesicle biomarkers in cancer research
Show more 3

Poster Presentations - Cell Death and Cancer Therapy

  • Abstract 610: Short peptides for targeted apoptosis in cancer cells: development & evaluation of therapeutic applications.
  • Abstract 596: Low-dose 1,25-dihydroxyvitamin D3 combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis.
  • Abstract 594: Dual regulation of cell death by Akt kinase inhibitor Mk-2206 in colorectal cancer.
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement